+44 (0) 28 9442 2413 Click here to view Randox Chinese website Click here to view Randox French website Click here to view Randox Polish website Click here to view Randox South Korea website
Reagents

Familial Hypercholesterolemia (FH) Arrays I & II

Rapid, simultaneous detection of 40 mutations within the LDLR, ApoB and PCSK9 genes

Familial Hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism. It is a common autosomal dominant, or inherited, disease which affects the plasma clearance of LDL-cholesterol (LDL-C), resulting in premature onset of cardiovascular disease (CVD) and a higher mortality risk.₁-₃

Common genetic defects in FH are mutations in three genes encoding proteins involved in the uptake of LDL-C from the plasma: the low density lipoprotein receptor (LDLR) gene (prevalence of 1 in 500), the apo-lipoprotein B (ApoB) gene (prevalence of 1 in 1000) and the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (prevalence of less than 1 in 2500).₁,₃

Patients who have one abnormal gene mutation are known as heterozygous. Heterozygous FH is a common genetic disorder, occurring in 1 person in 500 in most countries. Homozygous FH occurs when the patient has two abnormal gene mutations; however this is much rarer, with an occurrence of 1 in a million.₄

Early diagnosis of FH is crucial as by the time the heterozygous FH sufferer enters early adulthood they will have accumulated >20 years of continuous exposure to build up of fatty or lipid masses in arterial walls and are at a hundred-fold greater risk of a heart attack than other young people. Patients with homozygous FH are at such high risk that they may not live beyond childhood into early adulthood.₄

The UK National Institute for Health and Clinical Excellence (NICE) guidelines published in 2008 recommend that all FH patients be offered a DNA test to confirm the diagnosis and that identified mutations should be used as the basis for cascade testing of first-degree relatives of index cases. Patients newly identified by such screening can then be offered treatment to reduce the risk of premature cardiac events.₁

Only few countries currently have national genetic screening programs for FH despite evidence demonstrating that implementing such a program is highly cost-effective, particularly for cascade testing of known index cases as roughly 50% will have inherited the mutation.₅-₆

Clinical data

Several validation studies were completed using FH samples, with both blinded and un-blinded samples assessed. Total correlation of 98% was observed when using the Familial Hypercholesterolemia Arrays I & II.

Benefits of the Randox Familial Hypercholesterolemia (FH) Arrays I & II

To the patient:

To the laboratory:

References

₁Futema, M., et al. Analysis of the frequency and spectrum of mutations recognised to cause FH in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013; 229(1): 161-168.

₂ Williams, R.R., et al. Diagnosing Heterozygous Familial Hypercholesterolemia Using New Practical Criteria Validated by Molecular Genetics. American Journal of Cardiology 1993; 72:171-176.

₃Rader, D.J., Cohen J., Hobbs, H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. Journal of Clinical Investigation 2003; 111:1795-1803.

₄ Quereshi, N., Humphries, S.E., Seed, M., Rowlands, P., Minhas, R. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract 2009; 59: 773-778.

₅ Nordestgaard, B.G. et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society.

Eur Heart J 2013. Available online: http://eurheartj.oxfordjournals.org/content/early/2013/08/15/eurheartj.eht273.full.pdf+html.

Products

Contract Manufacturing

Product List 2014

Randox Engineering Randox accreditations